Cargando…

Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma()

The confinement of multiple myeloma (MM) to the bone marrow microenvironment requires an invasive bone marrow biopsy to monitor the malignant compartment. The existing clinical tools used to determine treatment response and tumor relapse are limited in sensitivity mainly because they indirectly meas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krishnan, Sabna Rajeev, Luk, Frederick, Brown, Ross D, Suen, Hayley, Kwan, Yiulam, Bebawy, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735625/ https://www.ncbi.nlm.nih.gov/pubmed/26806349 http://dx.doi.org/10.1016/j.neo.2015.11.011

Ejemplares similares

A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma
por: Rajeev Krishnan, Sabna, et al.
Publicado: (2020)

Circulating biosignatures in multiple myeloma and their role in multidrug resistance
por: Krishnan, S. Rajeev, et al.
Publicado: (2023)

Microparticles Mediate the Intercellular Regulation of microRNA-503 and Proline-Rich Tyrosine Kinase 2 to Alter the Migration and Invasion Capacity of Breast Cancer Cells
por: Gong, Joyce, et al.
Publicado: (2014)

Breast Cancer-Derived Microparticles Display Tissue Selectivity in the Transfer of Resistance Proteins to Cells
por: Jaiswal, Ritu, et al.
Publicado: (2013)

Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion
por: Jaiswal, Ritu, et al.
Publicado: (2017)

Microparticle conferred microRNA profiles - implications in the transfer and dominance of cancer traits
por: Jaiswal, Ritu, et al.
Publicado: (2012)

Proteome analysis of multidrug-resistant, breast cancer–derived microparticles
por: Pokharel, Deep, et al.
Publicado: (2014)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
por: Qasaimeh, Mohammad A., et al.
Publicado: (2017)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study
por: Dass, Jasmita, et al.
Publicado: (2019)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
por: Omstead, David T., et al.
Publicado: (2020)

Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma
por: Choudhuri, Jui, et al.
Publicado: (2023)

An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells
por: Nakayama, Shoko, et al.
Publicado: (2012)

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
por: Bae, Jooeun, et al.
Publicado: (2014)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
por: Soloveva, Maiia, et al.
Publicado: (2023)

PB2077: COMPARISON OF PLASMA CELL PERCENTAGE BY BONE MARROW ASPIRATE MORPHOLOGY AND CD138-STAINED BONE MARROW BIOPSY IN SMOLDERING MYELOMA TO PREDICT TRANSFORMATION TO SYMPTOMATIC MYELOMA
por: Cashman, Helen, et al.
Publicado: (2023)

Flow Cytometry Assessment of In Vitro Generated CD138(+) Human Plasma Cells
por: Itoua Maïga, Rayelle, et al.
Publicado: (2014)

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
por: Lee, Je-Jung
Publicado: (2010)

Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout
por: Jacak, Jaroslaw, et al.
Publicado: (2013)

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
por: KAWANO, YAWARA, et al.
Publicado: (2012)

Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells
por: KAWANO, YAWARA, et al.
Publicado: (2013)

Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells
por: Kishimoto, Renata Kiyomi, et al.
Publicado: (2016)

Comment on: “Validation of interphase fluorescence in situ hybridization (iFISH) of CD138 positive cells in multiple myeloma”()
por: Zalcberg Renault, Ilana
Publicado: (2016)

Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome
por: Li, Jing, et al.
Publicado: (2018)

Syndecan-1 (CD138), Carcinomas and EMT
por: Couchman, John R.
Publicado: (2021)

DEK protein level is a biomarker of CD138(positive) normal and malignant plasma cells
por: Çalışkaner, Zihni Onur, et al.
Publicado: (2017)

PB1956: EVALUATION OF AN INNOVATIVE NEW METHOD FOR QUANTITATION OF PLASMA CELLS ON CD138 IMMUNOHISTOCHEMISTRY
por: Gantana, E., et al.
Publicado: (2022)

Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
por: Cengiz, Arzu, et al.
Publicado: (2018)

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2018)

CD138(-) multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient
por: Wu, Dong, et al.
Publicado: (2020)

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma
por: Papadimitriou, Maria-Alexandra, et al.
Publicado: (2023)

CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery
por: Soike, Michael H., et al.
Publicado: (2019)

Deep Learning Accurately Quantifies Plasma Cell Percentages on CD138-Stained Bone Marrow Samples
por: Fu, Fred, et al.
Publicado: (2022)

Curcumin and its Derivatives: Their Application in Neuropharmacology and Neuroscience in the 21st Century
por: Lee, Wing-Hin, et al.
Publicado: (2013)

Paclitaxel-Fe(3)O(4) nanoparticles inhibit growth of CD138(−) CD34(−) tumor stem-like cells in multiple myeloma-bearing mice
por: Yang, Cuiping, et al.
Publicado: (2013)

High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma
por: Ibata, Soushi, et al.
Publicado: (2018)

Junctional adhesion molecule C expression specifies a CD138(low/neg) multiple myeloma cell population in mice and humans
por: Brandl, Andreas, et al.
Publicado: (2022)

Utility of CD-138 negative fraction for chromosome analysis in Plasma Cell Dyscrasias (PCD): a novel approach
por: Velagaleti, Gopalrao, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4b03mhtogko43lj4a9nvn2caku